Deadline: 25-Jan-23

The Research Investment for Global Health Technology (RIGHT) Fund Foundation is pleased to announce the nominations for Product Development Award that aim to develop vaccines, therapeutics, biologics or diagnostic platforms to alleviate infectious diseases with unmet health needs in Low- and Middle-Income Countries (LMICs).

Funds requested should be commensurate with the activities outlined in the proposal. The project team must include at least one Korean entity. Collaborative submission between Korean and non-Korean institutions are highly encouraged.

These reports suggest that

• Resources for health R&D are highly concentrated in the highincome countries,
• The resulting innovation, if left to commercial incentives alone, fail to benefit all and exacerbate health inequity, and
• Greater public oversight is needed to ensure innovation in health R&D benefits all.

The goal of the Product Development Award (PDA) is to support developing new or improved vaccines, therapeutics, biologics, or diagnostic platforms as global public good for prevention and control of infectious diseases that disproportionately affect the people in the Global South.

To achieve this goal, first, they e focus on infectious diseases that have a disproportionate burden of morbidity and mortality in low- and middle-income countries (LMICs) or diseases with a pandemic potential.

Award Type

• Target health conditions
  • Infectious diseases that disproportionately affect the people in the Low- and Middle-Income Countries (LMICs) or diseases with a pandemic potential
• Development stage
  • From or near the initiation of the clinical development or validation phase to regulatory approval and WHO prequalification (WHO PQ).
• Intervention types
  • Vaccines, therapeutics/biologics, diagnostics.
• Partnership requirement
  • Must include a Korean entity
  • Collaborative submission by multiple countries highly welcome and recommended.

Funding Information

• Up to 50%* of total project cost and up to 4 billion KRW/project for 3 years
• To be commensurated with the proposed scope

Eligibility for funding

• The RIGHT Foundation reserves the right to determine the eligibility of applicants and public health priority among the submitted proposals at its discretion.
• Partnership requirement
  • The applicant team must include at least one Korean entity with the expertise to make a significant contribution to the project Inclusion of nonKorean partner(s) especially those from the Global South is highly recommended.
• Korean entity
  • Korean companies (or entities with a research facility in Korea)
  • Not-for-profit research organizations and foundations
  • Government research institutions
  • Academic institutions
• Non-Korean entity
  • Life Science/Healthcare companies
  • Not-for-profit research organizations, foundations or product development partners
  • Government research institutions
  • Public health laboratories
  • Academic institutions.

Ineligible

• They will not consider funding for:
  • Discovery-phase proposals to identify pre-clinical candidates
  • Basic research studies of pathogen or human biology or host-pathogen interactions
  • Proposals without any data to support the proof of principle
  • Proposals for setting up research facilities or capital equipment.
  • Duplicate technologies without a substantive advantage over the current best practice
  • Concepts without a clear hypothesis or rationale for improved efficacy, potency, safety and/or ease of use over the current tools in clinical use or tools currently in development
  • Proposals with a target use-case that fails to reflect the gaps, needs and the end-users’ perspectives in LMICs
  • Development of products with characteristics that will pose a barrier to equitable access to the populations in LMICs.

For more information, visit Product Development Award.